Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Endocrinology
•
Hypertension
•
Primary Care
Can blood pressure measurements be reliably interpreted and obtained using forearm cuff pressures, especially for patients in certain situations such as obesity?
Related Questions
How do the results of the ESPRIT trial, which evaluated the impact of an SBP target of <120 mmHg on preventing major cardiovascular events, influence your blood pressure management goals for hypertensive patients with diabetes or a history of stroke?
What is the optimal BP target for patients with diabetes and hypertension to reduce their risk of MI/stroke?
Do you recommend adding low-dose Aspirin for primary prevention in patients with Type 2 Diabetes on Eliquis for another indication?
Do you recommend transitioning elderly patients from thiazide diuretics to alternative agents when managing hypertension given the increased concern for hyponatremia in this patient population?
Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?
Would you consider using Evenity in an elderly patient with rate controlled atrial fibrillation without history of MI or CVA?
How do you counsel patients on the likelihood of resolution of their hypertension post adrenalectomy for primary hyperaldosteronism?
What are your thoughts on the use of icosapent ethyl in clinical practice for patients with hypertriglyceridemia, and its safety profile such as increased risk of atrial fibrillation?
In the absence of clear guidelines, when would be a reasonable threshold to refer patients with resistant hypertension for renal denervation?
Does oral semaglutide provide similar cardiovascular risk reduction benefits as injectable semaglutide?
